# Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma

> **NCT01090089** · PHASE3 · COMPLETED · sponsor: **Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH** · enrollment: 348 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide, Dexamethasone
- **DRUG:** Lenalidomide, Dexamethasone, PBSCT

## Key facts

- **NCT ID:** NCT01090089
- **Lead sponsor:** Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-01
- **Primary completion:** 2020-01-31
- **Final completion:** 2020-01-31
- **Target enrollment:** 348 (ACTUAL)
- **Last updated:** 2023-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01090089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01090089, "Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01090089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*